Skip to main content
TipRanks
Go Ultimate75% OFF

Trinity Biotech (TRB0) AI Stock Analysis

0 Followers
DE:TRB0

Trinity Biotech

(Frankfurt:TRB0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring consumables modelConsumable reagents and test kits can generate repeat revenue as customer testing volumes continue, while instrument placements may create compatible follow-on demand. This model offers a durable base for customer retention and revenue visibility across healthcare settings.
Negative Factors
Stressed balance sheetPersistently negative equity and sharply rising debt reduce financial flexibility and increase refinancing exposure. A fragile capital structure can constrain investment in products and operations, while making the company more vulnerable if profitability or liquidity does not improve.

Trinity Biotech (TRB0) vs. iShares MSCI Germany ETF (EWG)

-5%0%5%10%15%DE:TRB00.00%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 123.53M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.1
Beta (1Y)
0.00
Revenue Growth
-19.82%
EPS Growth
44.49%
Country
Germany
Employees
287
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Trinity Biotech Business Overview & Revenue Model

Company Description

Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Afric...

Trinity Biotech Earnings Call Summary

Earnings Call Date:Nov 15, 2024(Q3-2024)|% Change Since:0.00%|Next Earnings Date:May 27, 2020
Earnings Call SentimentNeutral

The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.

Positive Updates

Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.

Negative Updates

Hemoglobin Revenue Decline
Hemoglobin revenues from A1c testing products were lower in Q3 2024 compared to Q3 2023, due to uneven ordering patterns and decreased instrument sales.

Company Guidance

During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.

Trinity Biotech Risk Analysis

Trinity Biotech disclosed 1 risk factors in its most recent earnings report. Trinity Biotech reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Trinity Biotech Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:TRB0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PRPOPRPO60Neutral$39.68M-36.61-7.84%―21.76%22.97%
INBSINBS54Neutral$5.84M-0.26-146.09%―36.55%60.09%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BNGOBNGO51Neutral$13.98M-0.37-85.00%―8.23%82.76%
BIAFBIAF42Neutral$4.00M-0.04-331.02%―-18.47%87.82%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:TRB0PRPOBNGOINBSBIAFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:TRB0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:TRB0Trinity Biotech63.600.000.00%
PRPOPrecipio22.131.105.23%
BNGOBionano Genomics1.00-0.50-33.33%
INBSIntelligent Bio Solutions Inc.1.76-5.16-74.57%
BIAFbioAffinity Technologies, Inc.2.20-21.50-90.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.